



No. JSPCS-23/016

Date 24 August 2023

Re: Progress report of the establishment of a new subsidiary and investing in a subsidiary
To: Director and manager, The Stock Exchange of Thailand

As you would be earlier informed, on 2 February 2023, JSP Pharmaceutical Manufacturing (Thailand) PCL. (the "Company") disclosed information no. JSPCS-23/002 in relation to establishment of a new subsidiary for investing in the academic laboratory research, scientific test and analysis, training and seminar, and consultancy for research fund application businesses of CDIP (Thailand) Public Company Limited ("CDIP"). Furthermore, on 18 April 2023, the Company disclosed information no. JSPCS-23/008 in relation to the resolutions of the Annual General Meeting of Shareholders for the year 2023, which approved the Company the connected and acquisition transactions of the ordinary shares of CDIP by the Company's subsidiary company to be newly established with consideration in cash amounted not exceed than Baht 200.0 million.

Presently, the Company has completed the establishment of a new subsidiary and investing in CDIP. As a result, both companies are the Company's subsidiaries with details as follow:

A new subsidiary	
The date on which the Board of Directors passed its resolution	2 February 2023
The date of establishment of subsidiary company	18 August 2023
Company name	JSP Pharma Holding Company Limited
Objective and business description	Invest in other businesses
Registered capital, number of shares and par value	Baht 200.0 million, divided to be 2,000,000 shares with par value of Baht 100 per share
Shareholding proportion	The Company have 100.0% ownership interest of the authorised capital
Name of directors	(1) Mrs. Jintana Santipisud (2) Mr. Sittichai Daengprasert (3) Ms. Jirada Daengprasert
Source of fund for establishment of subsidiary company	The proceeds received from the Initial Public Offering ("IPO") of the capital increase ordinary shares and the Company's working capital amounting to Baht 170.0 million and Baht 30.0 million, respectively.

บริษัท โรงงานเภสัชอุตสาหกรรม เจเอสพี
(ประเทศไทย) จำกัด (มหาชน)
255,257 ซอยสาธุประดิษฐ์ 58 แขวงบางโพงพาง
เขตยานนาวา กรุงเทพมหานคร 10120
โทรศัพท์ (Tel.) +66(2) 284-1218
โทรสาร (Fax) +66(2) 294-0705

JSP PHARMACEUTICAL MANUFACTURING
(THAILAND) PUBLIC COMPANY LIMITED
255,257 Soi Sathupradit 58 Bangpongpan,
Yannawa Bangkok 10120
Email : contact@jsppharma.com
Website : www.jsppharma.com



Investing in CDIP

The date on which the Shareholders passed its resolution	18 April 2023
The date of investment in subsidiary company	24 August 2023
Company name	CDIP (Thailand) Public Company Limited
Objective and business description	The academic laboratory research, scientific test and analysis, training and seminar, and consultancy for research fund application businesses
Registered capital, number of shares and par value	Baht 120.0 million, divided to be 240,000,000 shares with par value of Baht 0.50 per share
Shareholding proportion	JSP Pharma Holding Company Limited have 65.0% ownership interest of the authorised capital. The other shareholders who have 35.0% ownership interest are not connected person with the Company.
Name of directors	Four directors who are the Company's directors, which comprised (1) Mr. Sittichai Daengprasert (2) Mr. Pissanu Daengprasert (3) Ms. Jirada Daengprasert (4) Mr. Sorasit Daengprasert One other director (5) Mr. Soraphon Phantumapol

This transaction is considered as acquisition of investment in other company; which results other company becomes a subsidiary of a listed company; therefore, the Company is required to disclose information in accordance with the Regulations of the Stock Exchange of Thailand Re: Rules, Conditions and Procedures Governing the Disclosure of Information and Other Acts of a Listed Company.

Please be informed accordingly.

Sincerely yours,

JSP Pharmaceutical Manufacturing (Thailand) PCL.

Mr. Kriangkrai Rungruangthaweekul

Vice President of Finance

Investor Relations

Tel. 064 479 1691

Email ir@jsppharma.com